Phase 1A Study of the Safety of KSP/QRH Dimer
NCT03643068
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
26
Enrollment
OTHER
Sponsor class
Conditions
Healthy Adults
Interventions
DRUG:
KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg
DRUG:
KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg
Sponsor
University of Michigan